Lowell Therapeutics
Dr. Liu’s current research areas of interest focus on the predictive and pathogenetic role of biomarkers for both acute and chronic disease states. Her long-term goal is to identify and validate novel biomarkers of organ injury (specifically, the kidney and lung) that may have predictive value for disease outcomes as well as shed important insight into disease pathogenesis. In addition, she has a major interest in clinical trials in the ICU, with a particular focus on acute lung injury and acute kidney injury.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lowell Therapeutics
Lowell Therapeutics is developing a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU. The phase 3 primary endpoint for their product, Niyad, will be met by proving it anti-coagulates blood.